Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.

Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab. 2014 Aug 5;:jc20142372 Authors: Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M Abstract Background: Sclerostin, which is secreted exclusively by osteocytes, is a negative regulator of bone formation. The role of sclerostin in chronic kidney disease - mineral and bone disorder (CKD-MBD) is not well known. In the present study, we examined the relationship between serum sclerostin levels, bone turnover markers, and bone mineral density (BMD) of the radius in maintenance hemodialysis patients. Methods: This was a cross-sectional study that analyzed sclerostin, bone alkaline phosphatase (BAP, a bone formation marker), and tartrate-resistant acid phosphatase 5b (TRACP-5b, a bone resorption marker) in stored serum samples from 181 hemodialysis patients (68 ± 11 years, 105 males and 76 females, hemodialysis duration 6.9 ± 5.9 years). The BMD in the distal one-third of the radius and in the ultra-distal radius, which are enriched with cortical and cancellous bone, respectively, was examined by dual X-ray absorptiometry. Results: Serum sclerostin was 125 ± 53 pmol/L (mean ± SD). Serum sclerostin correlated significantly and negatively with serum BAP and TRACP-5b (r=-0.265. p
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research

Related Links:

Publication date: Available online 25 January 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Jiadela Teliewubai, Ximin Fan, Hongwei Ji, Rusitanmujiang Maimaitiaili, Jiamin Tang, Song Zhao, Shikai Yu, Chen Chi, Yawei Xu, Yi ZhangAbstractBackground and AimsMetabolic unhealthiness and obesity are both associated with an increased risk of cardiovascular disease. We aimed to investigate the significance of metabolic unhealthiness and obesity in organ damages in a community-based elderly cohort.Methods and results3325 elderly participants (>65 years old) were recruited in northern Shanghai. Associatio...
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Conclusion: The SBP at 7:00 AM, in addition to the 24-hour mSBP, is also associated with eGFR deterioration in patients with diabetic CKD, particularly in those with CKD stage 3-5. PMID: 31969922 [PubMed]
Source: Electrolyte and Blood Pressure - Category: Internal Medicine Tags: Electrolyte Blood Press Source Type: research
Among seriously ill patients, those with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD) arguably receive among the worst end-of-life care. These patients frequently die in the hospital, often after an intensive procedure like cardiopulmonary resuscitation, and with a low referral rate to hospice. There is now a concerted effort in the nephrology and palliative care communities to integrate palliative care into the treatment of these seriously ill patients. The Pathways Project is a national demonstration, funded by the Gordon and Betty Moore Foundation, to develop scalable innovations in kidney supportive care.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Guidelines recommend advance care planning (ACP) as essential to quality chronic kidney disease (CKD) management, but the nephrology community has yet to incorporate ACP upstream of the dialysis decision. Others have attempted to improve ACP for dialysis patients, but many patients report wishing they had been engaged in ACP earlier. This project tested integration of ACP coaching in the upstream setting of nephrology offices.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Authors: Kovesdy CP, Gosmanova EO, Woods SD, Fogli JJ, Rowan CG, Hansen JL, Sauer BC Abstract Objective: Patiromer is a sodium-free, non-absorbed, potassium (K+) binder approved for the treatment of hyperkalemia (HK). Among US Veterans with HK, this retrospective, observational cohort study evaluated patiromer utilization, RAASi continuation, and K+ concentration change following patiromer initiation.Methods: Using data from the Veterans Affairs Corporate Data Warehouse, Veterans with HK (K+ ≥5.1 mmol/L) were included upon patiromer initiation (index date) during the study period (1/2016-8/2018). All patien...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
Hypertension often occurs in patients with chronic kidney disease (CKD). Considering the decrease in serum Klotho and increase in serum FGF23 levels in such patients, decreased Klotho and increased FGF23 levels were thought to be associated with hypertension. Presympathetic neurons at the rostral ventrolateral medulla (RVLM) contribute to sympathetic activity and regulation of blood pressure. Therefore, we hypothesized that Klotho would reduce the activities of RVLM neurons and FGF23 would stimulate them.
Source: Autonomic Neuroscience: Basic and Clinical - Category: Neuroscience Authors: Source Type: research
Publication date: Available online 24 January 2020Source: American Journal of Kidney DiseasesAuthor(s): Darcy K. Weidemann, Alison G. Abraham, Jennifer L. Roem, Susan L. Furth, Bradley A. WaradyRationale &ObjectiveSoluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker associated with incident chronic kidney disease (CKD) and has been identified as an independent risk factor for CKD progression in children, although these findings remain preliminary, limited to a single point in time, and unreplicated in pediatric cohorts.Study DesignProspective longitudinal cohort study.Setting &Participants5...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: 25–31 January 2020Source: The Lancet, Volume 395, Issue 10220Author(s): Hiddo J L Heerspink, Hans-Henrik Parving, Dick de Zeeuw
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 25–31 January 2020Source: The Lancet, Volume 395, Issue 10220Author(s): Dongwei Liu, Zhangsuo Liu
Source: The Lancet - Category: General Medicine Source Type: research
Chronic kidney disease (CKD) is a known risk factor for post-HCT mortality. Currently, HCT-CI assigns a score of 2 for moderate-severe renal dysfunction based on serum creatinine (Cr), though Cr is not ideal marker of renal function and can be influenced by several factors. The aim of this study is to examine whether utilization of incremental degrees of renal dysfunction based on eGFR improves the utility of HCT-CI to predict allogeneic HCT outcomes.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 189 Source Type: research
More News: Chronic Kidney Disease | DEXA Scan | Dialysis | Endocrinology | Hemodialysis | Study | Urology & Nephrology